# Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis

> **NCT00648141** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 458 (actual)

## Conditions studied

- Spondylitis, Ankylosing

## Interventions

- **DRUG:** Celecoxib
- **DRUG:** Celecoxib
- **DRUG:** Diclofenac

## Key facts

- **NCT ID:** NCT00648141
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** —
- **Final completion:** 2005-01
- **Target enrollment:** 458 (ACTUAL)
- **Last updated:** 2008-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648141

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648141, "Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00648141. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*